The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML
Open accessAbstract
Summary Chimeric antigen receptor (CAR) therapy targeting CD19 has yielded remarkable outcomes in patients with acute lymphoblastic leukemia. To identify potential CAR targets in acute myeloid leukemia (AML), we probed the AML surfaceome for over-expressed molecules with tolerable systemic expression. We integrated large transcriptomics and proteomics data sets from malignant and normal tissues, and developed an algorithm to identify potential targets expressed in leukemia stem cells, but not in normal CD34+CD38− hematopoietic cells, T cells or vital tissues. As these investigations did not uncover candidate targets with a profile as favorable as CD19, we developed a generalizable combinatorial targeting strategy fulfilling stringent efficacy and safety criteria. Our findings indicate that several target pairings hold great promise for CAR therapy of AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt
Durinck, S., Spellman, P. T., Birney, E., & Huber, W. (2009) · Nature Protocols · doi:10.1038/nprot.2009.97 · Cited by 4,197
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Self-citationA draft map of the human proteome
Kim, M.-S., Pinto, S. M., Getnet, D., Nirujogi, R. S., Manda, S. S., Chaerkady, R., Madugundu, A. K., Kelkar, D. S., Isserlin, R., Jain, S., et al. (2014) · Nature · doi:10.1038/nature13302 · Cited by 2,198
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Self-citationCouzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051 · cited 1×
“Immunotherapy is emerging as an approach to treat cancer, based on the successes of antibody-mediated checkpoint blockade and engineered T cells (Couzin-Frankel, 2013).”
BackgroundMass-spectrometry-based draft of the human proteome
Wilhelm, M., Schlegl, J., Hahne, H., Gholami, A. M., Lieberenz, M., Savitski, M. M., Ziegler, E., Butzmann, L., Gessulat, S., Marx, H., et al. (2014) · Nature · doi:10.1038/nature13319 · Cited by 1,820
Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · cited 1×
“…non-lineage-restricted, type II transmembrane glycoprotein targeted by Daratumumab, the first U.S. Food and Drug Administration-approved anti-CD38 antibody (Dimopoulos et al., 2016; Lonial et al., 2016) the activity of which on AML is limited without all trans-retinoic acid (Yoshida et al., 2016).”
BackgroundB lymphocytes: how they develop and function
LeBien, T. W., & Tedder, T. F. (2008) · Blood · doi:10.1182/blood-2008-02-078071 · Cited by 1,400
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,254
Targeting of CD44 eradicates human acute myeloid leukemic stem cells
Jin, L., Hope, K. J., Zhai, Q., Smadja-Joffe, F., & Dick, J. E. (2006) · Nature Medicine · doi:10.1038/nm1483 · Cited by 1,219
Parkhurst, M. R., Yang, J. C., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,020
Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016 · cited 2×
“CAR therapy targeting CD19 has been particularly effective in acute lymphoblastic leukemia (ALL) (Sadelain, 2015), resulting in high CR rates in adults and children with chemorefractory disease (Davila et al., 2014; Lee et al., 2015; Maude et al., 2014a; Qasim et al., 2017; Turtle et al., 2016a).”
BackgroundLamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj2013 · Cited by 902
Therapeutic T cell engineering
Sadelain, M., Rivière, I., & Riddell, S. (2017) · Nature · doi:10.1038/nature22395 · Cited by 879
Self-citationKloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 857
Self-citationLonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854
Jordan, C., Upchurch, D., Szilvassy, S., Guzman, M., Howard, D., Pettigrew, A., Meyerrose, T., Rossi, R., Grimes, B., Rizzieri, D., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401903 · Cited by 821
Gardner, R., Wu, D., Cherian, S., Fang, M., Hanafi, L.-A., Finney, O., Smithers, H., Jensen, M. C., Riddell, S. R., Maloney, D. G., et al. (2016) · Blood · doi:10.1182/blood-2015-08-665547 · Cited by 749
Hills, R. K., Castaigne, S., Appelbaum, F. R., Delaunay, J., Petersdorf, S., Othus, M., Estey, E. H., Dombret, H., Chevret, S., Ifrah, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70281-5 · Cited by 721
Lamers, C. H., Sleijfer, S., van Steenbergen, S., van Elzakker, P., van Krimpen, B., Groot, C., Vulto, A., den Bakker, M., Oosterwijk, E., Debets, R., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.17 · Cited by 704
Remote control of therapeutic T cells through a small molecule–gated chimeric receptor
Wu, C.-Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015) · Science · doi:10.1126/science.aab4077 · Cited by 687
Pegram, H. J., Lee, J. C., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 678
Self-citationZah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M. C., & Chen, Y. Y. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0231 · Cited by 607
Kochenderfer, J. N., Dudley, M. E., Carpenter, R. O., Kassim, S. H., Rose, J. J., Telford, W. G., Hakim, F. T., Halverson, D. C., Fowler, D. H., Hardy, N. M., et al. (2013) · Blood · doi:10.1182/blood-2013-08-519413 · Cited by 590
Liu, X., Jiang, S., Fang, C., Yang, S., Olalere, D., Pequignot, E. C., Cogdill, A. P., Li, N., Ramones, M., Granda, B., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0159 · Cited by 565
Hudecek, M., Lupo-Stanghellini, M.-T., Kosasih, P. L., Sommermeyer, D., Jensen, M. C., Rader, C., & Riddell, S. R. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0330 · Cited by 544
Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse
Breems, D. A., Van Putten, W. L. J., Huijgens, P. C., Ossenkoppele, G. J., Verhoef, G. E. G., Verdonck, L. F., Vellenga, E., De Greef, G. E., Jacky, E., Van der Lelie, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.027 · Cited by 511
Gill, S., Tasian, S. K., Ruella, M., Shestova, O., Li, Y., Porter, D. L., Carroll, M., Danet-Desnoyers, G., Scholler, J., Grupp, S. A., et al. (2014) · Blood · doi:10.1182/blood-2013-09-529537 · Cited by 489
Wilkie, S., van Schalkwyk, M. C. I., Hobbs, S., Davies, D. M., van der Stegen, S. J. C., Pereira, A. C. P., Burbridge, S. E., Box, C., Eccles, S. A., & Maher, J. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9689-9 · Cited by 478
TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells
Kikushige, Y., Shima, T., Takayanagi, S.-I., Urata, S., Miyamoto, T., Iwasaki, H., Takenaka, K., Teshima, T., Tanaka, T., Inagaki, Y., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.11.014 · Cited by 477
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Grada, Z., Hegde, M., Byrd, T., Shaffer, D. R., Ghazi, A., Brawley, V. S., Corder, A., Schönfeld, K., Koch, J., Dotti, G., et al. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.32 · Cited by 458
Saito, Y., Kitamura, H., Hijikata, A., Tomizawa-Murasawa, M., Tanaka, S., Takagi, S., Uchida, N., Suzuki, N., Sone, A., Najima, Y., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000349 · Cited by 458
Downing, A. K., Knott, V, Werner, J. M., Cardy, C. M., Campbell, I. D., & Handford, P. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81259-3 · Cited by 446
Ritchie, D. S., Neeson, P. J., Khot, A., Peinert, S., Tai, T., Tainton, K., Chen, K., Shin, M., Wall, D. M., Hönemann, D., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.154 · Cited by 443
van Rhenen, A., van Dongen, G. A. M. S., Kelder, A., Rombouts, E. J., Feller, N., Moshaver, B., Walsum, M. S.-V., Zweegman, S., Ossenkoppele, G. J., & Jan Schuurhuis, G. (2007) · Blood · doi:10.1182/blood-2007-03-083048 · Cited by 439
Integrated Analysis of Transcriptomic and Proteomic Data
Haider, S., & Pal, R. (2013) · Current Genomics · doi:10.2174/1389202911314020003 · Cited by 431
Jacoby, E., Nguyen, S. M., Fountaine, T. J., Welp, K., Gryder, B., Qin, H., Yang, Y., Chien, C. D., Seif, A. E., Lei, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms12320 · Cited by 429
Kenderian, S. S., Ruella, M., Shestova, O., Klichinsky, M., Aikawa, V, Morrissette, J. J. D., Scholler, J., Song, D., Porter, D. L., Carroll, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.52 · Cited by 426
Wang, Q.-S., Wang, Y., Lv, H.-Y., Han, Q.-W., Fan, H., Guo, B., Wang, L.-L., & Han, W.-D. (2015) · Molecular Therapy · doi:10.1038/mt.2014.164 · Cited by 418
Caruso, H. G., Hurton, L. V., Najjar, A., Rushworth, D., Ang, S., Olivares, S., Mi, T., Switzer, K., Singh, H., Huls, H., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0139 · Cited by 397
New development in CAR-T cell therapy
Wang, Z., Wu, Z., Liu, Y., & Han, W. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0423-1 · Cited by 396
Walker, A. J., Majzner, R. G., Zhang, L., Wanhainen, K., Long, A. H., Nguyen, S. M., Lopomo, P., Vigny, M., Fry, T. J., Orentas, R. J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.008 · Cited by 383
CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia
Hosen, N., Park, C. Y., Tatsumi, N., Oji, Y., Sugiyama, H., Gramatzki, M., Krensky, A. M., & Weissman, I. L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704271104 · Cited by 379
Taussig, D. C. (2005) · Blood · doi:10.1182/blood-2005-03-1072 · Cited by 370
Krause, A., Guo, H.-F., Latouche, J.-B., Tan, C., Cheung, N.-K. V., & Sadelain, M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.4.619 · Cited by 365
Self-citationCasucci, M., Nicolis di Robilant, B., Falcone, L., Camisa, B., Norelli, M., Genovese, P., Gentner, B., Gullotta, F., Ponzoni, M., Bernardi, M., et al. (2013) · Blood · doi:10.1182/blood-2013-04-493361 · Cited by 357
Bagger, F. O., Sasivarevic, D., Sohi, S. H., Laursen, L. G., Pundhir, S., Sønderby, C. K., Winther, O., Rapin, N., & Porse, B. T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1101 · Cited by 298
Pizzitola, I., Anjos-Afonso, F., Rouault-Pierre, K., Lassailly, F., Tettamanti, S., Spinelli, O., Biondi, A., Biagi, E., & Bonnet, D. (2014) · Leukemia · doi:10.1038/leu.2014.62 · Cited by 287
Goodwin, R. G., Alderson, M. R., Smith, C. A., Armitage, R. J., VandenBos, T., Jerzy, R., Tough, T. W., Schoenborn, M. A., Davis-Smith, T., Hennen, K., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90133-b · Cited by 277
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
Paszkiewicz, P. J., Fräßle, S. P., Srivastava, S., Sommermeyer, D., Hudecek, M., Drexler, I., Sadelain, M., Liu, L., Jensen, M. C., Riddell, S. R., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84813 · Cited by 276
Self-citationDrent, E., Themeli, M., Poels, R., de Jong-Korlaar, R., Yuan, H., de Bruijn, J., Martens, A. C. M., Zweegman, S., van de Donk, N. W. C. J., Groen, R. W. J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.024 · Cited by 276
Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development
Zheng, J., Umikawa, M., Cui, C., Li, J., Chen, X., Zhang, C., Huynh, H., Kang, X., Silvany, R., Wan, X., et al. (2012) · Nature · doi:10.1038/nature11095 · Cited by 275
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions
Curran, K. J., Pegram, H. J., & Brentjens, R. J. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2604 · Cited by 251
Bakker, A. B. H., van den Oudenrijn, S., Bakker, A. Q., Feller, N., van Meijer, M., Bia, J. A., Jongeneelen, M. A. C., Visser, T. J., Bijl, N., Geuijen, C. A. W., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1659 · Cited by 247
CAR therapy: the CD19 paradigm
Sadelain, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80010 · Cited by 227
Self-citationHigh-performance web services for querying gene and variant annotation
Xin, J., Mark, A., Afrasiabi, C., Tsueng, G., Juchler, M., Gopal, N., Stupp, G. S., Putman, T. E., Ainscough, B. J., Griffith, O. L., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-0953-9 · Cited by 217
Designing chimeric antigen receptors to effectively and safely target tumors
Jensen, M. C., & Riddell, S. R. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.002 · Cited by 204
Davila, M. L., Kloss, C. C., Gunset, G., & Sadelain, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061338 · Cited by 185
Self-citationLynn, R. C., Poussin, M., Kalota, A., Feng, Y., Low, P. S., Dimitrov, D. S., & Powell, D. J. (2015) · Blood · doi:10.1182/blood-2014-11-612721 · Cited by 182
CD44v6: a target for antibody-based cancer therapy
Heider, K.-H., Kuthan, H., Stehle, G., & Munzert, G. (2004) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-003-0494-4 · Cited by 173
T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies
Shaffer, D. R., Savoldo, B., Yi, Z., Chow, K. K. H., Kakarla, S., Spencer, D. M., Dotti, G., Wu, M.-F., Liu, H., Kenney, S., et al. (2011) · Blood · doi:10.1182/blood-2010-04-278218 · Cited by 167
Tashiro, H., Sauer, T., Shum, T., Parikh, K., Mamonkin, M., Omer, B., Rouce, R. H., Lulla, P., Rooney, C. M., Gottschalk, S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.024 · Cited by 160
CD99 is a therapeutic target on disease stem cells in myeloid malignancies
Chung, S. S., Eng, W. S., Hu, W., Khalaj, M., Garrett-Bakelman, F. E., Tavakkoli, M., Levine, R. L., Carroll, M. P., Klimek, V. M., Melnick, A. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj2025 · Cited by 156
Gras, S. L., Günthert, U., Stauder, R., Curt, F., Oliferenko, S., Kluin‐Nelemans, H. C., Marie, J., Proctor, S., Jasmin, C., & Smadja‐Joffe, F. (1998) · Blood · doi:10.1182/blood.v91.9.3401 · Cited by 154
Law, C., Gordon, K. A., Toki, B. E., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2883 · Cited by 152
Arcangeli, S., Rotiroti, M. C., Bardelli, M., Simonelli, L., Magnani, C. F., Biondi, A., Biagi, E., Tettamanti, S., & Varani, L. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.017 · Cited by 152
Integrated transcriptome and proteome data: The challenges ahead
Hack, C. J. (2004) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/3.3.212 · Cited by 151
The cloning of CD70 and its identification as the ligand for CD27.
Bowman, M., Crimmins, M. A. V., Yetz-Aldape, J., Kriz, R., Kelleher, K. S., & Herrmann, S. H. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.4.1756 · Cited by 140
Álvarez‐Vallina, L., & Hawkins, R. E. (1996) · European Journal of Immunology · doi:10.1002/eji.1830261006 · Cited by 125
EMR1, an unusual member in the family of hormone receptors with seven transmembrane segments
Baud, V., Chissoe, S. L., Viégas-Pèquignot, E., Diriong, S., Cong, N. V., Roe, B. A., & Lipinski, M. (1995) · Genomics · doi:10.1016/0888-7543(95)80218-b · Cited by 123
High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity
Lynn, R. C., Feng, Y., Schutsky, K., Poussin, M., Kalota, A., Dimitrov, D. S., & Powell, D. J., Jr. (2016) · Leukemia · doi:10.1038/leu.2016.35 · Cited by 122
Estey, E. H., Kornblau, S. M., Pierce, S. A., Kantarjian, H. M., Beran, M., & Keating, M. J. (1996) · Blood · doi:10.1182/blood.v88.2.756.bloodjournal882756 · Cited by 109
McEarchern, J. A., Oflazoglu, E., Francisco, L. V., McDonagh, C. F., Gordon, K. A., Stone, I. J., Klussman, K., Turcott, E., van Rooijen, N., Carter, P. M., et al. (2006) · Blood · doi:10.1182/blood-2006-07-034017 · Cited by 106
Gemtuzumab Ozogamicin: Time to Resurrect?
Ravandi, F., Estey, E. H., Appelbaum, F. R., Lo‐Coco, F., Schiffer, C. A., Larson, R. A., Burnett, A. K., & Kantarjian, H. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0132 · Cited by 104
Human EMR2, a Novel EGF-TM7 Molecule on Chromosome 19p13.1, Is Closely Related to CD97
Lin, H., Stacey, M. A., Hamann, J., Gordon, S., & McKnight, A. J. (2000) · Genomics · doi:10.1006/geno.2000.6238 · Cited by 100
Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective
Rivière, I., & Sadelain, M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.034 · Cited by 96
Self-citationWeijtens, M. E. M., Hart, E., & Bolhuis, R. L. H. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301051 · Cited by 95
Yu, H., Sotillo, E., Harrington, C. T., Wertheim, G. B. W., Paessler, M. E., Maude, S. L., Rheingold, S. R., Grupp, S. A., Thomas‐Tikhonenko, A., & Pillai, V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24594 · Cited by 94
Maïga, A., Lemieux, S., Pabst, C., Lavallée, V.-P., Bouvier, M., Sauvageau, G., & Hébert, J. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.36 · Cited by 89
Ryan, M. C., Kostner, H., Gordon, K. A., Duniho, S. M., Sutherland, M. K., Yu, C., Kim, K. M., Nesterova, A., Anderson, M. E., McEarchern, J. A., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605816 · Cited by 88
Becker, P. S., Kantarjian, H. M., Appelbaum, F. R., Petersdorf, S. H., Storer, B. E., Pierce, S. A., Shan, J., Hendrie, P. C., Pagel, J. M., Shustov, A. R., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08831.x · Cited by 85
Chimeric antigen receptors: driving immunology towards synthetic biology
Sadelain, M. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.06.004 · Cited by 85
Self-citationTuratti, F., Figini, M., Balladore, E., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3180de5d90 · Cited by 77
Chimeric antigen receptor T-cell therapy for ALL
Maude, S. L., Shpall, E. J., & Grupp, S. A. (2014) · Hematology · doi:10.1182/asheducation-2014.1.559 · Cited by 71
Yoshida, T., Mihara, K., Takei, Y., Yanagihara, K., Kubo, T., Bhattacharyya, J., Imai, C., Mino, T., Takihara, Y., & Ichinohe, T. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.73 · Cited by 69
RNA-seq analysis of 2 closely related leukemia clones that differ in their self-renewal capacity
Wilhelm, B. T., Briau, M., Austin, P., Faubert, A., Boucher, G., Chagnon, P., Hope, K. J., Girard, S., Mayotte, N., Landry, J., et al. (2010) · Blood · doi:10.1182/blood-2010-07-293332 · Cited by 65
Expression of Ig-Like Transcript 4 Inhibitory Receptor in Human Non-small Cell Lung Cancer
Sun, Y., Liu, J., Gao, P., Wang, Y., & Liu, C. (2008) · CHEST Journal · doi:10.1378/chest.07-1100 · Cited by 57
Towards Curative Cancer Immunotherapy: Overcoming Posttherapy Tumor Escape
Zhou, G., & Levitsky, H. I. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/124187 · Cited by 53
Lin, H., Stubbs, L. J., & Mucenski, M. L. (1997) · Genomics · doi:10.1006/geno.1997.4674 · Cited by 48
Strassberger, V., Gutbrodt, K. L., Krall, N., Roesli, C., Takizawa, H., Manz, M. G., Fugmann, T., & Neri, D. (2014) · Journal of Proteomics · doi:10.1016/j.jprot.2014.01.022 · Cited by 32
Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy
Perna, F., & Sadelain, M. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.08.15 · Cited by 24
Self-citationThe quest for spatio-temporal control of CAR T cells
Sun, J., & Sadelain, M. (2015) · Cell Research · doi:10.1038/cr.2015.131 · Cited by 13
Self-citation
Cited by
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,331
Self-citationTumor Antigen Escape from CAR T-cell Therapy
Majzner, R. G., & Mackall, C. L. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0442 · Cited by 1,183
Senolytic CAR T cells reverse senescence-associated pathologies
Amor, C., Feucht, J., Leibold, J., Ho, Y.-J., Zhu, C., Alonso-Curbelo, D., Mansilla-Soto, J., Boyer, J. A., Li, X., Giavridis, T., et al. (2020) · Nature · doi:10.1038/s41586-020-2403-9 · Cited by 1,098
Self-citationCancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
Engineering living therapeutics with synthetic biology
Cubillos-Ruiz, A., Guo, T., Sokolovska, A., Miller, P. F., Collins, J. J., Lu, T. K., & Lora, J. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00285-3 · Cited by 356
Metadata
- Authors
- Perna, F., Berman, S. H., Soni, R. K., Mansilla-Soto, J., Eyquem, J., Hamieh, M., Hendrickson, R. C., Brennan, C. W., & Sadelain, M.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 32
- Issue
- 4
- Pages
- 506-519.e5
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2761903029
- Cited by
- 346
- References
- 108
- FWCI
- 10.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.